Clinigen's lifecycle platform simplifies our pharma clients' partnering strategy by enabling them to utilise multiple access solutions across a medicine's lifecycle.

BeiGene

Over the last 12 months Clinigen has been working with BeiGene – a global biopharmaceutical company with multiple medicines on the market in the United States and China and more reaching key stages of the development process.

BeiGene has a significant pipeline including three internally-developed molecules approved for different life-threatening cancer types. The most advanced of the three molecules, zanubrutinib, a BTK inhibitor, has already been approved in major territories such as the USA and China and further approvals in Europe and other countries and regions are expected. Tislelizumab, an immuno-oncology drug and checkpoint inhibitor that is approved for several indications in China, delivered positive global phase 3 development studies; approvals in the USA, Europe and other territories are planned. And pamiparib, which is approved in China for the treatment of ovarian cancer.

There were three key priorities for BeiGene:
- Enable investigator-led research exploring treatment options for targeted indications, specific subgroups of patients or hypothesis generating work.
- Enabling compliant and controlled access to their oncology portfolio for treatment of unmet medical needs
- Fast and efficient delivery of their licensed medications post approval.

CLINIGEN IS A KEY PARTNER FOR US IN ENABLING ACCESS TO OUR MEDICINES ACROSS THE MEDICINE'S LIFECYCLE. WE ARE ABLE TO UTILISE THEIR PLATFORM AT VARIOUS STAGES FOR DIFFERING ACCESS CHALLENGES ACROSS MULTIPLE PRODUCTS – THIS IS EXTREMELY IMPORTANT FOR US AS IT SUPPORTS OUR MISSION OF PROVIDING ACCESS TO MORE PATIENTS, SIMPLIFIES OUR PARTNERING STRATEGY AND STREAMLINES OUR APPROACH.

WHERE ARE CLINIGEN AND BEIGENE WORKING TOGETHER:

SERVICES

CLINICAL

Investigator-led research can be critical in further understanding molecules and their appropriate application. Co-ordination and facilitation of requests from global sites can however be complex, resource intensive and often requires a nimble and responsive supply chain. Clinigen receiving and facilitating these requests on behalf of BeiGene helps to ensure compliant and timely responses and builds and maintains important relationships with key sites.

MANAGED ACCESS

BeiGene is committed to ensuring appropriate patients with unmet medical needs can access their molecules prior to commercial availability in a compliant manner. As a result BeiGene has initiated key programs: to enable access to zanubrutinib, tislelizumab and pamiparib where their physician deems it the most suitable treatment option over existing commercial therapies. Clinigen has worked with BeiGene to design, implement and deliver these programs to ensure no eligible patient request goes unanswered.

PRODUCTS

PARTNERED

Should zanubrutinib be approved in the EU, BeiGene will want to ensure smooth and efficient commercial roll-out in key markets as soon as possible. Whilst BeiGene is expanding its European footprint and medical functions to prepare, it also needs a distribution partner in the UK following Brexit. Clinigen will be that partner, facilitating UK commercial distribution following commercial launch.

WE'RE SIMPLIFYING PARTNERING STRATEGIES